Imagine what if?

We believe that cell therapy may have the biggest impact for patients who have diseases where cells die and are not replaced by the body’s natural response.

We have built a pipeline focused on investigating new therapies to treat neurological, cardiovascular, immunological and ophthalmic diseases.

Bluerock pipeline

Area
Neurology
Clinical Indication
Parkinson’s Disease bemdaneprocel (BRT-DA01)
Cell Type
Dopaminergic Neuron
Green bar indicating Phase 3 status
Area
Neurology
Clinical Indication
Parkinson’s Disease (BR-DA02)
Cell Type
Dopaminergic Neuron
Area
Neurology
Clinical Indication
Neurodegenerative Disease
Cell Type
Microglia
Area
Neurology
Clinical Indication
Genetic or aquired myelin defects
Cell Type
Oligodendrocyte
Area
Ophthalmology In partnership with Opsis Therapeutics
Clinical Indication
Primary photoreceptor diseases (OpCT-001)
Cell Type
Photoreceptor
OpCT-001 Phase 1 status bar
Area
Ophthalmology In partnership with Opsis Therapeutics
Clinical Indication
Early / Intermediate Dry AMD
Cell Type
Retinal Pigment Epithelium (RPE)
Area
Ophthalmology In partnership with Opsis Therapeutics
Clinical Indication
Late Dry AMD / GA
Cell Type
Photoreceptor + RPE
Area
Cardiology
Clinical Indication
Heart Failure (BR-CM01)
Cell Type
Cardiomyocyte
Area
Immunology In partnership with bit.bio
Clinical Indication
Autoimmune Disease
Cell Type
CD4+ T-Reg